Nevertheless, direct evidence from the test set indicated that MPS-II patients in the MYCN-amplified group had a significantly higher survival rate than those in MPS-I (p < 0.05), suggesting that MPS stratification may have clinical potential to further differentiate patients from the MYCN-amplified group. The gene discussed is MYCN; the disease is mucopolysaccharidosis type 2.